David Pelizzon Sells 302,369 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 302,369 shares of OrthoPediatrics stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the sale, the director directly owned 6,201,764 shares in the company, valued at $130,299,061.64. This trade represents a 4.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

OrthoPediatrics Price Performance

Shares of OrthoPediatrics stock opened at $22.06 on Friday. The firm has a market cap of $575.99 million, a PE ratio of -13.13 and a beta of 0.99. The stock has a 50 day moving average of $22.01 and a 200 day moving average of $19.04. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. OrthoPediatrics Corp. has a 12 month low of $14.42 and a 12 month high of $26.74.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The business had revenue of $70.51 million for the quarter, compared to analysts’ expectations of $68.21 million. On average, research analysts expect that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Key Stories Impacting OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics crossed the $70 million revenue level and reportedly increased its guidance, signaling continued demand for its pediatric orthopedic products and potentially stronger future growth. OrthoPediatrics Crosses $70M as Guidance Climbs Higher
• Positive Sentiment: Analyst sentiment remains favorable: nine analysts rate the stock Buy, one rates it Hold and one rates it Sell. The consensus rating is Moderate Buy with an average price target of $26.44; BTIG and Needham recently raised their targets to $29 and $35, respectively.
• Positive Sentiment: Institutional ownership is substantial at approximately 69%, while several investment firms—including Millennium Management, BlackRock, Granahan Investment Management and Wasatch Advisors—have recently increased or initiated positions.
• Neutral Sentiment: Reported short interest was zero shares as of September 10, leaving no meaningful short-covering catalyst or bearish short-position overhang.
• Negative Sentiment: Director David Pelizzon, also identified in related filings as major shareholder entities associated with Jennifer Pritzker and Squadron Capital, sold 302,369 shares at an average price of $21.01 for approximately $6.35 million. The sale reduced the reported holding by 4.65%, which may pressure sentiment, although the insider still retained about 6.2 million shares. SEC Insider Sale Filing

Institutional Investors Weigh In On OrthoPediatrics

Large investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in OrthoPediatrics by 6.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after purchasing an additional 645 shares during the last quarter. Millennium Management LLC boosted its stake in shares of OrthoPediatrics by 55.3% during the first quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock worth $16,172,000 after buying an additional 233,873 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of OrthoPediatrics by 112.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock valued at $4,937,000 after purchasing an additional 106,041 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of OrthoPediatrics in the first quarter valued at approximately $389,000. Finally, American Century Companies Inc. raised its stake in shares of OrthoPediatrics by 12.5% during the second quarter. American Century Companies Inc. now owns 34,486 shares of the company’s stock worth $741,000 after purchasing an additional 3,828 shares during the last quarter. 69.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

KIDS has been the topic of a number of analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. BTIG Research upped their price objective on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Weiss Ratings upgraded OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Truist Financial set a $22.00 price objective on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Finally, TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.44.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.